# US 2015/0104387 A1 · Psma-targeting compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104387 A1
- Document ID: US20150104387A1
- Status: Published application
- Kind: A1
- Application number: 14/243,535
- Filed: 2014-04-02
- Published: 2015-04-16
- Earliest claimed: 2009-03-19
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: MARTIN G. POMPER; RONNIE C. MEASE; YING CHEN; Sangeeta Ray
- Web page: https://patentgrep.com/patent/US20150104387A1

## CPC

- C07D 257/02: not condensed with other rings
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 51/0421: {having six-membered rings with one oxygen as the only ring hetero atom}
- A61K 51/044: {having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin A61K51/0459)}
- A61K 51/0446: {having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil}
- A61K 51/0453: {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- A61K 51/0472: {containing heavy metals, e.g. hemin, hematin, melarsoprol}
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 209/24: with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
- C07D 213/04: having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 255/02: not condensed with other rings
- C07D 311/14: substituted in position 6 and unsubstituted in position 7
- C07D 311/20: hydrogenated in the hetero ring
- C07D 311/82: Xanthenes
- C07F 5/027: {Organoboranes and organoborohydrides}
- C07F 13/005: {Compounds without a metal-carbon linkage}
- G01N 33/5091: {for testing the pathological state of an organism}
- A61P 35/00: Antineoplastic agents
- G01N 2800/342: Prostate diseases, e.g. BPH, prostatitis
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.

## Claims

### Claim 1

A compound having the structure
wherein the subunits associated with elements p, q, r, and s may be in any order;
Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4;
R is each independently H or C1-C4 alkyl;
r is 0 or 1;
Tz is a triazole group selected from the group consisting of
L1 is
L2 is
X1 is —NRC(O)—, —NRC(O)NR—, —NRC(S)NR—, or —NRC(O)O—;
X2 is —C(O)NR—, —NRC(O)NR—, —NRC(S)NR—, or —OC(O)NR—;
R5 is H, CO2H, or CO2R6, where R6 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl;
b is 1, 2, 3, or 4;
d is 1, 2, 3, or 4;
q is O or 1;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein if one of R2 and R3 is CO2H or CO2R4, then the other is H;
n is 1, 2, 3, 4, 5 or 6;
s is O or 1;
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O)—;
m is 1, 2, 3, 4, 5, or 6;
p is O, 1, 2, or 3, and when p is 2 or 3, each R1 may be the same or different;
R1 is H, C1-C6 alkyl, C2-Ci2 aryl, or C4-C16 alkylaryl;
G is a moiety selected from the group consisting of
where Ch is a metal chelating moiety, optionally including a chelated metal; FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum; one of A and A1 is Ch and the other is FG; V and V′ are independently —C(O)—, —NRC(O)—, —NRC(S)—, or —OC(O)—; and g is 1, 2, 3, 4, 5, or 6;
with the condition that:
when G is
and r is 0, then q and s are both 1;
when G is
and r is 0, then q and s are both 0 or both 1;
when G is then p is 0 and R2 is H, and the structure optionally includes a chelated metal ion;
Ch when G is
and r is 0, then if p is 0, then one of R2 and R3 is CO2R4, and the other is H; and
when g is
then r is 0.

### Claim 2 (depends on 1)

A compound according to claim 1 having the structure
wherein Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4;
R is each independently H or C1-C4 alkyl,
Ch is a metal chelating moiety optionally including a chelated metal;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
V is —C(O)—, —NRC(O)—, —NRC(S)—, or —OC(O)—;
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
p is 0, 1, 2, or 3, and when p is 2 or 3, each R1 may be the same or different;
R1 is H, C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein when one of R and R is CO2H or CO2R4, the other is H, and when p is 0, one of R2 and R3 is CO2R4, and the other is H.

### Claim 3 (depends on 2)

A compound according to claim 2 selected from the group consisting of

### Claim at position 4

4-23. (canceled)

### Claim 24 (depends on 1)

A compound according to claim 1 wherein Ch is selected from the group consisting of

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A compound according to claim 1, having a chelated metal, wherein the chelated metal is Tc, In, Ga, Y, Lu, Re, Cu, Ac, Bi, Pb, Sm, Sc, Co, Ho, Gd, Eu, Tb, or Dy.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 2)

A compound according to claim 2 selected from the group consisting of

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim at position 13

32-44. (canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50 (depends on 1)

A compound according to claim 1 having the structure
where p, q, and s are in the order drawn, and q and s are either both 0 or both 1;
wherein Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4;
FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum;
R is each independently H or C1-C4 alkyl;
V is —C(O)— or —NRC(O)— or —NRC(S)—;
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein if one of R2 and R3 is CO2H or CO2R4, then the other is H;
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
p is O, 1, 2, or 3, and when p is 2 or 3, each R1 may be the same or different;
R1 is H, Cj-C6 alkyl, C2-Ci2 aryl, or C4-C16 alkylaryl
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein when one of R2 and R3 is CO2H or CO2R4, the other is H.

### Claim 51 (depends on 50)

A compound according to claim 50 selected from the group consisting of
wherein Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4
FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum;
R is each independently H or Ci-C4 alkyl;
V is —C(O)— or —NRC(O)— or —NRC(S)—;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
a is 1, 2, 3, or 4;
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
p is 0, 1, 2, or 3, and when p is 2 or 3, each R1 may be the same or different;
R1 is H, C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein when one of R2 and R3 is CO2H or CO2R4, the other is H;

### Claim at position 21

52-74. (canceled)

### Claim 75 (depends on 1)

A compound according to claim 1 wherein FG is a fluorescent dye moiety which emits in the near infrared spectrum.

### Claim 76 (depends on 1)

A compound according to claim 1 wherein FG comprises carbocyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine and merocyanine, polymethine, coumarine, rhodamine, xanthene, fluorescein, boron-dipyrromethane (BODIPY), Cy5, Cy5.5, Cy7, VivoTag-680, VivoTag-S680, VivoTag-S750, AlexaFluor660, AlexaFluor680, AlexaFluor700, AlexaFluor750AlexaFluor790, Dy677, Dy676, Dy682, Dy752, Dy780, DyLight547, Dylight647, HiLyte Fluor 647, HiLyte Fluor 680, HiLyte Fluor 750, IRDye 800CW, IRDye 800RS, IRDye 700DX, ADS780WS, ADS830WS, and ADS832WS.

### Claim 77 (depends on 1)

A compound according to claim 1 wherein FG has the a structure selected from the group consisting of

### Claim 78 (depends on 50)

A compound according to claim 50 selected from the group consisting of

### Claim 79 (depends on 1)

A compound according to claim 1 having the structure
wherein Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4;
one of A and A′ is Ch and the other is FG, where FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum and Ch is metal chelating moiety optionally including a chelated metal.
R is each independently H or C1-C4 alkyl;
V or V′ are independently —C(O)—, —NRC(O)—, or —NRC(S)—;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
g is 1, 2, 3, 4, 5, or 6;
p is 0, 1, 2, or 3, and when p is 2 or 3, each R1 may be the same or different;
R1 is H, C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein when one of R2 and R3 is CO2H or CO2R4, the other is H.

### Claim 80 (depends on 79)

A compound according to claim 79 having the structure selected from the group consisting of

### Claim at position 28

81-102. (canceled)

### Claim 103 (depends on 79)

A compound according to claim 79 having the structure

### Claim at position 30

104-112. (canceled)

### Claim 113 (depends on 79)

A compound according to claim 79 having the structure

### Claim 114 (depends on 1)

A compound according to claim 1 having the structure
wherein the subunits associated with elements p, q, r, and s may be in any order;
Z is tetrazole or CO2Q; each Q is independently selected from hydrogen or a protecting group, a is 1, 2, 3, or 4;
R is each independently H or C1-C4 alkyl,
r is 1
Tz is a triazole group selected from the group consisting of
L1 is
L2 is
X1 is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, or —NRC(O)O—;
X2 is —C(O)NR—, —NRC(O)NR—, NRC(S)NR—, or —OC(O)NR—;
R5 is H, CO2H, or CO2R6, where R6 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl;
b is 1, 2, 3, or 4;
d is 1, 2, 3, or 4;
q is 0 or 1;
W is —NRC(O)—, —NRC(O)NR—, NRC(S)NR—, —NRC(O)O—, —OC(O)NR—, —OC(O)—, —C(O)NR—, or —C(O)O—
n is 1, 2, 3, 4, 5 or 6;
R2 and R3 are independently H, CO2H, or CO2R4, where R4 is a C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl, wherein if one of R2 and R3 is CO2H or CO2R4, then the other is H;
s is 0 or 1;
Y is —C(O)—, —NRC(O)—, —NRC(S)—, —OC(O);
m is 1, 2, 3, 4, 5, or 6;
p is 0, 1, 2, or 3, and when p is 2 or 3, each R1 may be the same or different;
R1 is H, C1-C6 alkyl, C2-C12 aryl, or C4-C16 alkylaryl;
G1 is a moiety selected from the group consisting of
where Ch is a metal chelating moiety, optionally including a chelated metal; FG is a fluorescent dye moiety which emits in the visible or near infrared spectrum; one of A and A′ is Ch and the other is FG; V is —C(O)—, —NRC(O)—, —NRC(S)—, or —OC(O)—; and g is 1, 2, 3, 4, 5, or 6.

### Claim 115 (depends on 114)

A compound according to claim 114 having the structure selected from the group consisting of

### Claim at position 34

116-145. (canceled)

### Claim 146 (depends on 1)

A method of imaging one or more cells, organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1, where the compound includes a fluorescent dye moiety, or a metal isotope suitable for imaging.

### Claim 147 (depends on 1)

A method of treating a tumor comprising administering a therapeutically effective amount of a compound according to claim 1, where the compound includes a therapeutically effective radioisotope.

### Claim 148 (depends on 1)

A method for sorting cells by exposing the cells to a compound according to claim 1, where the compound includes a fluorescent dye moiety, followed by separating cells which bind the compound from cells which do not bind the compound.

### Claim 149 (depends on 1)

A method for intraoperative tumor mapping comprising administering an effective amount of a compound according to claim 1, where the compound includes a fluorescent dye moiety.

### Claim 150 (depends on 1)

A kit comprising a compound according to claim 1.
